Fiche publication
Date publication
mai 2002
Journal
Cytometry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BARBERI-HEYOB Muriel
,
Pr MERLIN Jean-Louis
,
Dr MIRJOLET Céline
Tous les auteurs :
Mirjolet JF, Didelot C, Barberi-Heyob M, Merlin JL
Lien Pubmed
Résumé
Bromodeoxyuridine (BrdU) cell cycle analysis using flow cytometry is of clinical interest for making treatment decisions or for predicting response and survival, through proliferation rate (labeling index or S-phase fraction) assessment or T(pot) calculation. Thymidylate synthase expression was tested in vitro, in vivo, and clinically as a prognostic factor for 5-fluorouracil (5FU) sensitivity. However, results were still controversial. Moreover, we had reported that 5FU sensitivity was related to the labeling index of untreated cell cultures.
Mots clés
Adenocarcinoma, Antimetabolites, Antimetabolites, Antineoplastic, toxicity, Breast Neoplasms, Bromodeoxyuridine, Coloring Agents, Female, Flow Cytometry, Fluorouracil, toxicity, G1 Phase, drug effects, Head and Neck Neoplasms, Humans, Pancreatic Neoplasms, Propidium, Resting Phase, Cell Cycle, drug effects, S Phase, drug effects, Tumor Cells, Cultured, cytology
Référence
Cytometry. 2002 May;48(1):6-13
